The effects of the intraperitoneal administration of midazolam on blood glucose level and serum lipids in streptozotocin-induced diabetes in rats.
In male Wistar rats rendered diabetic by streptozotocin administration, the intraperitoneal (i.p.) injection of midazolam (2.5-5.0 and 10 mg/kg) induced a significant reduction of hyperglycemia and hyperlipidemia. The plasma immunoreactive insulin level was slightly, but significantly increased. The lethality was diminished.